European patients pay the true price of government intervention in drug pricing

European patients are facing the true cost of government interventions in setting drug prices, according to reports highlighting the complex interplay between national healthcare strategies and international regulatory pressures. The situation has been exacerbated by policies introduced under the Trump administration, which have had far-reaching effects on pharmaceutical pricing across both continents. These measures, known as "Most Favored Nation" (MFN) provisions, were proposed in May 2025 and gradually implemented starting in 2026. They tie the prices of prescription drugs dispensed in American pharmacies to the lowest equivalent price among 19 OECD member countries, including 14 European Union (EU) states. In response, most EU member states use an international reference pricing system, aligning drug costs based on a group of reference countries and adopting the lowest common denominator.

The result has been a domino effect across two continents, where a single European decision to set a lower price becomes the standard for American manufacturers thousands of kilometers away. Additionally, external pressures such as a proposed 15% import tax on pharmaceutical products, announced by the Trump administration in April 2026, further complicate the landscape. As a consequence, European countries face intense pressure to increase drug prices. Otherwise, they risk losing future pharmaceutical investments due to compressed profits on the American market—the world's largest pharmaceutical market—caused by artificially low prices in their own countries.

In response, decision-makers within the EU are examining the adoption of a unified countermeasure, with the apparent logic being that they hold more negotiation power when working together than when acting separately. However, a broader governmental intervention in the pharmaceutical sector is not the solution; rather, it is the problem that explains why patients in the Union find themselves in such a vulnerable position from the outset.

Pricing alignment policies were adopted to keep costs at a minimum and ensure long-term sustainability of health budgets. Yet these policies have worsened access to treatments for patients. Similar to any price cap scenario, when governments allocate resources at a price below market rates, demand exceeds supply. Consumers face shortages and rationing, translating into waiting lists for certain products. Indeed, the median time for a medication’s availability is already 532 days across the entire Union, according to the latest W.A.I.T. survey, ranging from 56 days in Germany to 1,201 days (the highest) in Romania.

MFN proposals introduce even more uncertainty, forcing pharmaceutical companies to delay the launch of new products in the European market. For instance, the company Insmed postponed the introduction of its anti-inflammatory drug Brinsupri in Germany, citing unclear MFN pricing regimes. Specifically, a prolonged waiting period translates into human suffering, manifesting as diseases that otherwise would not have existed or treatable conditions becoming chronic.

More seriously, externally imposed pricing regimes have cost Europeans—and the world—numerous medical breakthroughs. Europe was once a leader in innovation in natural sciences, responsible for 55% of new medicines developed globally in the 1970s. This changed with the emergence of the current pricing model, which deprived pharmaceutical companies of the high margins necessary to invest in revolutionary medicines.

As a result, capital and research have shifted to the United States. By the early 2000s, America generated 57% of innovative pharmaceutical products, compared to just 31% in Europe. Today, 40% of new medicines developed in the U.S. never reach patients in the EU. The impact of price caps is so severe that these measures reduce annual research and development efforts significantly.

The ripple effects of these policies extend beyond mere financial implications. They influence the global trajectory of medical innovation, affecting not only the availability of new treatments but also the pace at which they are developed. With pharmaceutical companies increasingly focusing their efforts and resources on markets offering greater profitability, the potential for groundbreaking discoveries diminishes. This shift underscores a critical challenge faced by European nations: balancing the need for affordable healthcare with the imperative to foster continued medical innovation. The dilemma lies in ensuring that the pursuit of cost containment does not come at the expense of progress in healthcare advancements.